COMP <GO>
ACRV vs CING // NET PROFIT MARGIN
Acrivon Therapeutics Inc. (NASDAQ) VS. Cingulate Inc. (NASDAQ) • 15-METRIC TALLY: ACRV 1
— CING 2
■ METRIC PARITY
LAST: $1.66 (-5.68%) • MKT CAP: $75.4M
net-margins
—
LAST: $4.98 (-4.05%) • MKT CAP: $75.5M
net-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ACRV VS. CING)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ACRV | CING | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -23.06% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | ACRV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.9 | 51.6 | -12.72 | CING | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $75.4M | $75.5M | -$50.2K | CING | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ACRV REV | CING REV | ACRV GROSS % | CING GROSS % | ACRV FCF | CING FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$65.3M | -$17.4M |
| FY 2024 | $0 | $0 | — | — | -$68.4M | -$18.7M |
| FY 2023 | $0 | $0 | — | — | -$42.6M | -$15.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ACRV // BETA —
CING // BETA —